EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Finalist

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future 

CAMBRIDGE, Mass. – Apr 17, 2024 –Ernst & Young LLP (EY US) today announced that Liang Schweizer, PhD, CEO, Chairperson, and Founder of HiFiBiO Therapeutics was named an Entrepreneur Of The Year® 2024 New England Award finalist. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive business award for audacious leaders who disrupt markets, revolutionize sectors and have a transformational impact on lives. Over the past four decades, the program has recognized the daring entrepreneurs with big ideas and bold actions that reshape our world. 

Dr. Schweizer was one of 27 regional entrepreneurs selected as finalists by an independent panel of judges. The candidates were evaluated based on their demonstration of building long-term value through entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes. 

Dr. Schweizer remarked: “I am honored to be nominated among the visionary business leaders in New England. This recognition speaks highly to HiFiBiO Therapeutics’ innovative and paradigm-shifting approach to discover and develop immunotherapies for patients with cancer and autoimmune disorders. Every day, we make progress towards developing more effective therapeutics for each and every patient in need. I am extremely proud to be recognized as a finalist among so many other accomplished entrepreneurs across different industries.” 

HiFiBiO Therapeutics is a clinical stage biotech company pioneering novel approaches for immune modulation. In 5 short years, the company has discovered and developed a robust pipeline of innovative immune therapies including 8 clinical candidates identified as first-in-class or best-in-class through its groundbreaking Drug Intelligence Science (DIS®) platform. Three of these candidates are currently progressing through Phase 1a/1b immune-oncology trials: a first-in-class TNFR2 agonist (HFB200301, NCT05238883), a best-in-class BTLA antagonist (HFB200603, NCT05789069), and a next-generation OX40 agonist (HFB301001, NCT05229601). The company also embraces a global open innovation model, partnering with esteemed institutions to develop cutting edge technology solutions and immune therapies to positively impact patient lives.  

Entrepreneur Of The Year honors many different types of business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future. 

Regional award winners will be announced on June 12th, 2024 during a special celebration, and will become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. The winners will then be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies. 

In addition to Entrepreneur Of The Year, EY US supports other entrepreneurs through the EY Entrepreneurial Winning Women™ program and the EY Entrepreneurs Access Network to help connect women founders and Black and Hispanic/Latino entrepreneurs, respectively, with the resources, network and access needed to unlock their full potential. 



Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, Marsh USA, SAP and the Ewing Marion Kauffman Foundation. In New England, sponsors also include a premier sponsor, DLA Piper. 

About Entrepreneur Of The Year®  

Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 80 countries and territories globally. 

The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the World Entrepreneur Of The Year® competition. Visit 

About EY 

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets. 

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate. 

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today. 

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit 

About HiFiBiO Therapeutics  

HiFiBiO Therapeutics is a clinical stage biotech pioneering a unique high-resolution translational platform (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® platform and has been recognized as one of 2023’s Fierce 15 biotech companies. Additional information can be found at